Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.03
RAD's Cash-to-Debt is ranked lower than
95% of the 360 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.53 vs. RAD: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
RAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.03 Max: 0.1
Current: 0.03
0
0.1
Equity-to-Asset 0.05
RAD's Equity-to-Asset is ranked lower than
96% of the 361 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. RAD: 0.05 )
Ranked among companies with meaningful Equity-to-Asset only.
RAD' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.35  Med: 0.09 Max: 0.55
Current: 0.05
-0.35
0.55
Interest Coverage 1.24
RAD's Interest Coverage is ranked lower than
95% of the 320 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.24 vs. RAD: 1.24 )
Ranked among companies with meaningful Interest Coverage only.
RAD' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 1.23 Max: 2.22
Current: 1.24
0.02
2.22
Piotroski F-Score: 5
Altman Z-Score: 2.75
Beneish M-Score: -2.45
WACC vs ROIC
5.81%
2.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 1.64
RAD's Operating Margin % is ranked lower than
67% of the 361 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.05 vs. RAD: 1.64 )
Ranked among companies with meaningful Operating Margin % only.
RAD' s Operating Margin % Range Over the Past 10 Years
Min: -7.81  Med: 1.23 Max: 3.32
Current: 1.64
-7.81
3.32
Net Margin % 0.01
RAD's Net Margin % is ranked lower than
79% of the 362 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.78 vs. RAD: 0.01 )
Ranked among companies with meaningful Net Margin % only.
RAD' s Net Margin % Range Over the Past 10 Years
Min: -11.09  Med: -0.7 Max: 7.95
Current: 0.01
-11.09
7.95
ROE % 0.66
RAD's ROE % is ranked higher than
75% of the 354 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.67 vs. RAD: 0.66 )
Ranked among companies with meaningful ROE % only.
RAD' s ROE % Range Over the Past 10 Years
Min: -1148.43  Med: -32.62 Max: 51.83
Current: 0.66
-1148.43
51.83
ROA % 0.04
RAD's ROA % is ranked lower than
77% of the 364 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.31 vs. RAD: 0.04 )
Ranked among companies with meaningful ROA % only.
RAD' s ROA % Range Over the Past 10 Years
Min: -29.43  Med: -2.45 Max: 26.83
Current: 0.04
-29.43
26.83
ROC (Joel Greenblatt) % 12.25
RAD's ROC (Joel Greenblatt) % is ranked lower than
52% of the 363 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.45 vs. RAD: 12.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RAD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -44.02  Med: 8.35 Max: 22.13
Current: 12.25
-44.02
22.13
3-Year Revenue Growth Rate 5.90
RAD's 3-Year Revenue Growth Rate is ranked lower than
65% of the 318 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. RAD: 5.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RAD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16  Med: 1.8 Max: 19.6
Current: 5.9
-16
19.6
3-Year EBITDA Growth Rate -3.50
RAD's 3-Year EBITDA Growth Rate is ranked lower than
53% of the 285 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.20 vs. RAD: -3.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RAD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -84.8  Med: 2.1 Max: 43.8
Current: -3.5
-84.8
43.8
3-Year EPS without NRI Growth Rate -74.10
RAD's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 252 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.30 vs. RAD: -74.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RAD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -74.1  Med: 6.1 Max: 479.9
Current: -74.1
-74.1
479.9
GuruFocus has detected 1 Warning Sign with Rite Aid Corp $RAD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RAD's 30-Y Financials

Financials (Next Earnings Date: 2017-06-29)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

RAD Guru Trades in Q2 2016

Leucadia National 857,991 sh (New)
Jeremy Grantham 2,382,600 sh (New)
John Burbank 14,678 sh (New)
David Einhorn 10,330,000 sh (New)
Jim Simons 5,295,600 sh (+5521.66%)
John Paulson 580,900 sh (+120.46%)
Mario Gabelli 1,385,875 sh (+29.85%)
Paul Tudor Jones 122,800 sh (unchged)
George Soros Sold Out
Joel Greenblatt Sold Out
Pioneer Investments 919,826 sh (-0.16%)
Paul Tudor Jones 83,605 sh (-16.89%)
» More
Q3 2016

RAD Guru Trades in Q3 2016

Paul Singer 3,179,854 sh (New)
Eric Mindich 3,078,000 sh (New)
Jeremy Grantham 3,889,139 sh (+63.23%)
Pioneer Investments 1,326,427 sh (+44.20%)
Leucadia National 1,208,291 sh (+40.83%)
David Einhorn 13,443,035 sh (+30.14%)
Paul Singer 2,000,000 sh (unchged)
Paul Tudor Jones 122,800 sh (unchged)
Jim Simons Sold Out
John Paulson Sold Out
John Burbank Sold Out
Mario Gabelli 1,369,975 sh (-1.15%)
Paul Tudor Jones 52,162 sh (-37.61%)
» More
Q4 2016

RAD Guru Trades in Q4 2016

First Pacific Advisors 169,000 sh (New)
David Einhorn 20,462,962 sh (+52.22%)
Paul Tudor Jones 122,800 sh (unchged)
Leucadia National Sold Out
Paul Singer Sold Out
Eric Mindich Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments 1,294,187 sh (-2.43%)
Mario Gabelli 1,191,650 sh (-13.02%)
Jeremy Grantham 2,047,600 sh (-47.35%)
» More
Q1 2017

RAD Guru Trades in Q1 2017

Leucadia National 102,100 sh (New)
Jeremy Grantham 3,565,000 sh (+74.11%)
Mario Gabelli 1,228,344 sh (+3.08%)
Paul Singer 3,424,600 sh (unchged)
First Pacific Advisors Sold Out
David Einhorn 16,778,989 sh (-18.00%)
Pioneer Investments 740,142 sh (-42.81%)
» More
» Details

Insider Trades

Latest Guru Trades with RAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Rite Aid Corp

SymbolPriceYieldDescription
RADCO0.000.00Conv Pfd Shs Series -I-

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446110    SIC: 5912
Compare:OTCPK:CLCGY, NAS:PETS, OTCPK:RADLY, NYSE:GNC, OTCBB:COCP, NAS:CJJD, OTCPK:OMHE, OTCPK:HEWA, NAS:WBA » details
Traded in other countries:RTA.Germany,
Headquarter Location:USA
Rite Aid Corp operates retail drugstore chains in the United States. It operates approximately 4,561 stores in 31 states across the country and in the District of Columbia.

Rite Aid is a large retail drugstore chain in the United States. The company reports via two segments: retail pharmacy and pharmacy services. The retail pharmacy segment generates revenue primarily through the sale of prescription drugs, along with an assortment of merchandise that includes over-the-counter medications, health and beauty aids, personal-care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other everyday consumables. The pharmacy-services segment relates to EnvisionRx, a fully owned subsidiary that operates as a pharmacy benefit management provider offering a broad range of pharmaceutical services.

Guru Investment Theses on Rite Aid Corp

David Einhorn Comments on Rite Aid - May 17, 2017

RAD (NYSE:RAD) fell from $8.24 to $4.25. We had expected that Walgreens and RAD would satisfy regulatory concerns and close the merger at $9 per share. Instead, the deal was re-cut to between $6.50 and $ 7.00, and even at this date, the regulatory concerns are not resolved. We are watching the situation carefully and we have trimmed the position, as our original thinking was incorrect.





  • From Einhorn's first-quarter 2017 shareholder commentary.


Check out David Einhorn latest stock trades

Top Ranked Articles about Rite Aid Corp

David Einhorn Comments on Rite Aid Guru stock highlight
RAD (NYSE:RAD) fell from $8.24 to $4.25. We had expected that Walgreens and RAD would satisfy regulatory concerns and close the merger at $9 per share. Instead, the deal was re-cut to between $6.50 and $ 7.00, and even at this date, the regulatory concerns are not resolved. We are watching the situation carefully and we have trimmed the position, as our original thinking was incorrect. Read more...
Stocks Reach Their 3-Year Lows Dr. Reddy's Laboratories Ltd., Rite Aid Corp., World Fuel Services Corp. and Target Corp have reached their respective three-year lows
Dr. Reddy's Laboratories Ltd. (NYSE:RDY), Rite Aid Corp. (NYSE:RAD), World Fuel Services Corp (NYSE:INT) and Target Corp (NYSE:TGT) have reached their three-year lows. Read more...
Walgreens, Rite Aid Reduce Price, Postpone Closing of Merger Deal’s value reduced by at least $2 billion
Walgreens Boots Alliance (NASDAQ:WBA) and Rite Aid Corp. (NYSE:RAD) announced on Monday they are reducing the price and postponing the close of their definitive merger agreement. Read more...
David Einhorn Adds Calpine, Rite Aid, Amaya to Portfolio The guru’s top 3 new holdings
David Einhorn (Trades, Portfolio) of Greenlight Capital acquired three new holdings during the second quarter. They are Calpine Corp. (NYSE:CPN), Rite Aid Corp. (NYSE:RAD) and Amaya Inc. (NASDAQ:AYA). Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 370.37
RAD's Forward PE Ratio is ranked lower than
100% of the 172 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.81 vs. RAD: 370.37 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 6.29
RAD's PB Ratio is ranked lower than
93% of the 361 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.81 vs. RAD: 6.29 )
Ranked among companies with meaningful PB Ratio only.
RAD' s PB Ratio Range Over the Past 10 Years
Min: 0.29  Med: 2.83 Max: 151.55
Current: 6.29
0.29
151.55
PS Ratio 0.11
RAD's PS Ratio is ranked higher than
86% of the 358 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.47 vs. RAD: 0.11 )
Ranked among companies with meaningful PS Ratio only.
RAD' s PS Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.11 Max: 0.34
Current: 0.11
0.01
0.34
Price-to-Operating-Cash-Flow 17.06
RAD's Price-to-Operating-Cash-Flow is ranked higher than
60% of the 198 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.59 vs. RAD: 17.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RAD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.53  Med: 8.43 Max: 94.42
Current: 17.06
0.53
94.42
EV-to-EBIT 22.81
RAD's EV-to-EBIT is ranked lower than
71% of the 441 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.48 vs. RAD: 22.81 )
Ranked among companies with meaningful EV-to-EBIT only.
RAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -2331.6  Med: 21.95 Max: 3761.3
Current: 22.81
-2331.6
3761.3
EV-to-EBITDA 10.44
RAD's EV-to-EBITDA is ranked higher than
55% of the 453 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.29 vs. RAD: 10.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
RAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.2  Med: 12.4 Max: 17.3
Current: 10.44
-6.2
17.3
Current Ratio 1.69
RAD's Current Ratio is ranked higher than
70% of the 345 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.21 vs. RAD: 1.69 )
Ranked among companies with meaningful Current Ratio only.
RAD' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.86 Max: 3.98
Current: 1.69
0.81
3.98
Quick Ratio 0.74
RAD's Quick Ratio is ranked lower than
55% of the 345 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.75 vs. RAD: 0.74 )
Ranked among companies with meaningful Quick Ratio only.
RAD' s Quick Ratio Range Over the Past 10 Years
Min: 0.18  Med: 0.52 Max: 1
Current: 0.74
0.18
1
Days Inventory 40.57
RAD's Days Inventory is ranked lower than
53% of the 350 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.37 vs. RAD: 40.57 )
Ranked among companies with meaningful Days Inventory only.
RAD' s Days Inventory Range Over the Past 10 Years
Min: 40.29  Med: 62.34 Max: 70.58
Current: 40.57
40.29
70.58
Days Sales Outstanding 19.68
RAD's Days Sales Outstanding is ranked lower than
57% of the 268 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.41 vs. RAD: 19.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
RAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.31  Med: 13.58 Max: 19.68
Current: 19.68
7.31
19.68
Days Payable 23.50
RAD's Days Payable is ranked lower than
77% of the 264 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 48.66 vs. RAD: 23.50 )
Ranked among companies with meaningful Days Payable only.
RAD' s Days Payable Range Over the Past 10 Years
Min: 21.83  Med: 25.18 Max: 29.42
Current: 23.5
21.83
29.42

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.70
RAD's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 196 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.70 vs. RAD: -2.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.8  Med: -2.7 Max: 1.5
Current: -2.7
-25.8
1.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.94
RAD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
73% of the 207 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.48 vs. RAD: 1.94 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RAD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.46  Med: 2.45 Max: 10.79
Current: 1.94
1.46
10.79
Price-to-Median-PS-Value 1.07
RAD's Price-to-Median-PS-Value is ranked lower than
73% of the 302 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. RAD: 1.07 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RAD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 2.23 Max: 8.1
Current: 1.07
0.09
8.1
Earnings Yield (Greenblatt) % 4.40
RAD's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 488 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.09 vs. RAD: 4.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RAD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 4.2 Max: 8.2
Current: 4.4
0.3
8.2
Forward Rate of Return (Yacktman) % 14.39
RAD's Forward Rate of Return (Yacktman) % is ranked higher than
77% of the 234 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.25 vs. RAD: 14.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RAD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -33.7  Med: 0.8 Max: 56.7
Current: 14.39
-33.7
56.7

More Statistics

Revenue (TTM) (Mil) $32,845
Beta1.83
Short Percentage of Float3.56%
52-Week Range $3.32 - 8.77
Shares Outstanding (Mil)1,052.37

Analyst Estimate

Feb18
Revenue (Mil $)
EPS ($) 0.01
EPS without NRI ($) 0.01
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RAD

Headlines

Articles On GuruFocus.com
Health Dialog Provides Nurse Line Services to Kern Health Systems' Population Health Program May 22 2017 
David Einhorn Comments on Rite Aid May 17 2017 
David Einhorn's Greenlight Capital First-Quarter Commentary 2017 May 17 2017 
Health Dialog and National Electric Cooperative to Share Successful Strategies for 10-Year Populatio May 09 2017 
David Einhorn Doesn't Think Much of Tesla, Isn't Done With General Motors Apr 27 2017 
InvestorsObserver releases covered-call reports for Lam Research, Verizon Communications, Rite Aid, Apr 20 2017 
Walgreens Boots Alliance: Strong Outlook Regardless of Rite Aid Outcome Apr 13 2017 
Stocks Reach Their 3-Year Lows Mar 25 2017 
David Einhorn Buys Buffett’s Monsanto, Retail, Apple in Q4 Feb 15 2017 
Walgreens, Rite Aid Reduce Price, Postpone Closing of Merger Jan 30 2017 

More From Other Websites
ETFs with exposure to Rite Aid Corp. : May 22, 2017 May 22 2017
Health Dialog Provides Nurse Line Services to Kern Health Systems' Population Health Program May 22 2017
Can Rite Aid Stock Bounce Back After Last Week's 12% Drop? May 21 2017
Options Traders Expect Huge Moves in Rite Aid (RAD) Stock May 19 2017
Drug distributor McKesson's profit beats, shares jump May 18 2017
David Einhorn's Greenlight Capital First-Quarter Commentary 2017 May 17 2017
Eyes Are on McKesson's Guidance May 17 2017
Amazon is breaking into the pharmacy market May 17 2017
Today's Research Reports on Stocks to Watch: Staples and Rite Aid May 17 2017
Rite Aid Shares Slide 8% After Report of Increased FTC Activity May 16 2017
Why Rite Aid, H&R Block, and NantKwest Slumped Today May 16 2017
Walgreens Gives FTC Deadline on Rite Aid Ruling May 16 2017
Rite Aid, Fred Shares Down on Report of Stepped Up FTC Action May 16 2017
Feds increase scrutiny of Walgreens-Rite Aid merger May 16 2017
Cramer's lightning round: 'I foresee pain' for this FTC-embroiled pharma play May 10 2017
J. P. Morgan Commercial Mortgage Finance Corp. 2000-C9 -- Moody's Affirms Two Classes of JPMC... May 10 2017
Final countdown starts on Walgreens/Rite Aid merger; Fred's awaits outcome May 09 2017
Walgreens, Rite Aid Start The Clock For FTC To OK Merger May 09 2017
Health Dialog and National Electric Cooperative to Share Successful Strategies for 10-Year... May 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)